Latest & greatest articles for ace inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ace inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ace inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ACE inhibitors

Angiotensin converting enzyme inhibitors (ACE) are principally used to reduce blood pressure. ACE inhibitors work by reducing the activity of the renin-angiotensin-aldosterone system. They have been used in a variety of conditions, including hypertension, acute myocardial infarctions, left ventricular systolic dysfunction and diabetic nephropathy

Ace inhibitors can be used alone to treat hypertension, or they can be used in combination with other drugs such as diuretics. Case studies and clinical trials on the medicine show that it can be used to prevent stroke or heart attacks. Common side effects of the drug including hypotension, dry cough, hyperkalaemia, headache, dizziness, fatigue, nausea, renal impairment and swelling in the lips and tongue.

ACE Inhibitors are widely used and feature extensively in the literature including clinical guidelines, systematic reviews, randomised controlled trials, case studies etc. These can easily be found via a search of the Trip Database. Medical research is vital to the development of new treatments and therapies for hypertension.

Top results for ace inhibitors

1. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people (Full text)

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) ? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Heart Actions . 2020 Jul 31;heartjnl-2020-317393. doi: 10.1136/heartjnl-2020-317393. Online ahead of print. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin

2020 EvidenceUpdates PubMed abstract

2. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis (Full text)

Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology Information (...) Cite Share Permalink Copy Page navigation Heart Actions . 2020 Jul 1;heartjnl-2020-317336. doi: 10.1136/heartjnl-2020-317336. Online ahead of print. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis # , # , , , , , , , Affiliations Expand Affiliations 1 Department of Medical Sciences, University of Ferrara, Ferrara, Emilia-Romagna, Italy. 2 Polytechnic University of Marche School of Medicine and Surgery, Ancona, Marche, Italy. 3 University Hospital of Ferrara

2020 EvidenceUpdates PubMed abstract

3. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials. (Full text)

ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials. The advantages of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in reducing risk of cardiovascular events (CVEs) and delaying end-stage kidney disease (ESKD) in patients with chronic kidney disease (CKD) is well-known. However, the efficacy and safety of these agents (...) in non-dialysis CKD stages 3-5 patients are still a controversial issue.Two investigators (Yaru Zhang and Dandan He) independently searched and identified relevant studies from MEDLINE (from 1950 to October 2018), EMBASE (from 1970 to October 2018), and the Cochrane Library database. Randomised clinical trials in non-dialysis CKD3-5 patients treated with renin-angiotensin system (RAS) inhibitors were included. We used standard criteria (Cochrane risk of bias tool) to assess the inherent risk of bias

2020 Drugs PubMed abstract

4. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers

Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser. Did you (...) know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. . ESC sub specialties communities Search Read your latest personalised notifications No account yet? Don't miss out Read your latest personalised notifications Loading quicklinks... Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers 13 Mar 2020 Based on initial reports from China, and subsequent evidence

2020 European Society of Cardiology

5. Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19

in the diagram:: Angiotensinogen is converted to angiotensin I by renin. Angiotensin I (a decapeptide) is converted by ACE-1 to angiotensin II (an octapeptide). Angiotensin II is an agonist at both angiotensin AT 1 and angiotensin AT 2 receptors. Angiotensin I is also converted, by ACE-2, to the nonapeptide angiotensin(1-9). Angiotensin II is also converted, by ACE-2, to the heptapeptide angiotensin(1-7). Angiotensin (1-9) is converted, by ACE-1, to angiotensin(1-7). ACE-1 inhibitors inhibit the conversion (...) or the action of another protease, cathepsin (b) The same serine protease, TMPRSS2, causes irreversible conformational changes in the virus’s S2 subunits, activating them, after which the virus fuses to the cell membrane and can be internalized by the cell A serine protease inhibitor, camostat mesylate, used in Japan to treat , inhibits the TMPRSS2 and partially into bronchial epithelial cells in vitro. Analysis Reducing the activity of ACE-2 in cell membranes could theoretically reduce the ability of SARS

2020 Oxford COVID-19 Evidence Service

6. Should ACE Inhibitors and Angiotensin II Receptor Blockers be Stopped for COVID-19

Should ACE Inhibitors and Angiotensin II Receptor Blockers be Stopped for COVID-19 MOH-ACE COVID-19 RAPID REVIEW 21 March 2020 Page 1 of 2 Clinical evidence Background Should ACE inhibitors and angiotensin II receptor blockers be stopped for COVID-19? This write-up summarises a rapid evidence review related to COVID-19. The information may be revised as new evidence emerges. Two recent articles by Madeddu in the British Medical Journal (BMJ) and Fang et al. in the Lancet Respiratory Medicine (...) have raised concerns about angiotensin-converting enzyme inhibitors (ACE-i) and angiotensin II receptor blockers (ARB) potentially increasing the risk of COVID-19 and related respiratory distress syndrome. 1,2 The authors hypothesise that angiotensin-converting enzyme 2 (ACE2) is upregulated in patients treated with ACE-i or ARB, which would facilitate COVID-19 infection as ACE2 is a functional receptor of the virus. 3 Madeddu maintains that ACE-i and ARB should not be suspended due to the lack

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

7. Chronic kidney disease: ACE-inhibitors and AIIRAs

an ACE-inhibitor, after each dose increase, and regularly throughout treatment. Hyperkalaemia — monitor serum electrolytes 1–2 weeks after starting an ACE-inhibitor, after each dose increase, and regularly throughout treatment. Cough — occurs in about 15% of people taking an ACE-inhibitor, and may occur at any time after starting treatment. If troublesome (for example, affecting sleep) and other causes have been excluded, consider switching to an AIIRA which do not inhibit the breakdown of bradykinin (...) Chronic kidney disease: ACE-inhibitors and AIIRAs ACE-inhibitors and AIIRAs | Prescribing information | Chronic kidney disease | CKS | NICE Search CKS… Menu ACE-inhibitors and AIIRAs Chronic kidney disease: ACE-inhibitors and AIIRAs Last revised in May 2020 ACE-inhibitors and AIIRAs Contraindications and cautions Use of angiotensin-converting enzyme (ACE) inhibitors is contraindicated in people: With a history of angio-oedema associated with previous exposure to an ACE-inhibitor

2020 NICE Clinical Knowledge Summaries

8. Take It or Leave It: A Meta-analysis of Perioperative ACE Inhibitors and ARBs. (Abstract)

Take It or Leave It: A Meta-analysis of Perioperative ACE Inhibitors and ARBs. 30113970 2019 11 20 1526-7598 127 3 2018 09 Anesthesia and analgesia Anesth. Analg. Take It or Leave It: A Meta-analysis of Perioperative ACE Inhibitors and ARBs. 589 10.1213/ANE.0000000000003686 Nathan Naveen N Northwestern University Feinberg School of Medicine (n-nathan@northwestern.edu). eng Journal Article United States Anesth Analg 1310650 0003-2999 2018 8 17 6 0 2018 8 17 6 0 2018 8 17 6 1 ppublish 30113970

2019 Anesthesia and Analgesia

9. ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients

ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients View/ Open Date 2009-01 Format (...) Metadata Abstract Avoid prescribing an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) for patients at high risk of vascular events or renal dysfunction. The combination does not reduce poor outcomes, and leads to more adverse drug-related events than an ACE inhibitor or ARB alone. Stength of recommendation: B: 1 large, high-quality randomized controlled trial (RCT). URI Part of Citation Journal of Family Practice, 58(1) 2009: 24+. Rights OpenAccess. This work

2019 PURLS

10. ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients

ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients View/ Open Date 2009-01 Format (...) Metadata Abstract Avoid prescribing an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) for patients at high risk of vascular events or renal dysfunction. The combination does not reduce poor outcomes, and leads to more adverse drug-related events than an ACE inhibitor or ARB alone. Stength of recommendation: B: 1 large, high-quality randomized controlled trial (RCT). URI Part of Citation Journal of Family Practice, 58(1) 2009: 24+. Rights OpenAccess. This work

2019 PURLS

11. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis. (Full text)

Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis. Current heart failure (HF) guidelines recommend titrating angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) and beta-blockers (BBs) to target doses used in pivotal placebo-controlled randomized controlled trials (RCTs). Despite a number of RCTs comparing different doses (i.e

2019 PLoS ONE PubMed abstract

12. ACE inhibitors

ACE inhibitors Top results for ace inhibitors - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 (...) or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ace inhibitors The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other

2018 Trip Latest and Greatest

13. Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies. (Full text)

Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies. Oxidative stress is increased in hyperuricemic patients with acute myocardial infarction (AMI). Use of sulfhydryl ACE-inhibitors (ACEIs), such as zofenopril or captopril, plus xanthine oxidase inhibitors (XOIs), may potentially result in enhanced

2018 BMC Cardiovascular Disorders PubMed abstract

14. Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP?

Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes (...) and normal BP? View/ Open Date 2017-04 Format Metadata Abstract Q: Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Evidence-based answer: Yes for angiotensin-converting enzyme (ACE) inhibitors, no for angiotensin receptor blockers (ARBs). In normotensive patients with type 1 and type 2 diabetes, ACE inhibitor therapy reduces the risk of developing diabetic kidney disease, defined as new-onset microalbuminuria or macroalbuminuria, by 18% (strength

2018 Clinical Inquiries

15. Combined therapy with beta-blockers and ACE-inhibitors/angiotensin receptor blockers and recurrence of Takotsubo (stress) cardiomyopathy: A meta-regression study. (Abstract)

Combined therapy with beta-blockers and ACE-inhibitors/angiotensin receptor blockers and recurrence of Takotsubo (stress) cardiomyopathy: A meta-regression study. 28040283 2017 11 09 2017 11 09 1874-1754 230 2017 Mar 01 International journal of cardiology Int. J. Cardiol. Combined therapy with beta-blockers and ACE-inhibitors/angiotensin receptor blockers and recurrence of Takotsubo (stress) cardiomyopathy: A meta-regression study. 281-283 S0167-5273(16)34615-0 10.1016/j.ijcard.2016.12.124 (...) -Converting Enzyme Inhibitors therapeutic use Drug Therapy, Combination Recurrence Takotsubo Cardiomyopathy diagnosis prevention & control surgery ACE-inhibitors/angiotensin receptor blockers Beta-blockers Combined therapy Meta-regression Prevention Recurrence Takotsubo (stress) cardiomyopathy 2016 08 01 2016 12 16 2016 12 17 2017 1 4 6 0 2017 11 10 6 0 2017 1 2 6 0 ppublish 28040283 S0167-5273(16)34615-0 10.1016/j.ijcard.2016.12.124

2017 International journal of cardiology

16. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. (Full text)

ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. Among adolescents with type 1 diabetes, rapid increases in albumin excretion during puberty precede the development of microalbuminuria and macroalbuminuria, long-term risk factors for renal and cardiovascular disease. We hypothesized that adolescents with high levels of albumin excretion might benefit from angiotensin-converting-enzyme (ACE) inhibitors and statins, drugs that have not been fully evaluated in adolescents.We (...) screened 4407 adolescents with type 1 diabetes between the ages of 10 and 16 years of age and identified 1287 with values in the upper third of the albumin-to-creatinine ratios; 443 were randomly assigned in a placebo-controlled trial of an ACE inhibitor and a statin with the use of a 2-by-2 factorial design minimizing differences in baseline characteristics such as age, sex, and duration of diabetes. The primary outcome for both interventions was the change in albumin excretion, assessed according

2017 NEJM Controlled trial quality: predicted high PubMed abstract

17. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab. (Full text)

Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab. Administration of anthracycline chemotherapy ± trastuzumab is associated with cardiac dysfunction. We sought to identify whether prophylactic administration of angiotensin converting enzyme (ACE) inhibitor or beta-blocker attenuates subsequent left ventricular dysfunction and heart failure.Electronic databases were searched for studies examining the effect (...) of beta-blockers or ACE inhibitors on left ventricular ejection fraction (LVEF) and heart failure in patients receiving anthracycline chemotherapy ± trastuzumab. The end-point was change in LVEF or development of heart failure.Eight studies (1048 patients) were identified. There was no difference in the change in LVEF (weighted mean difference (MWD) - 4.74 (95% confidence interval (CI): -12.6 to 3.1), p = 0.24) or risk of new heart failure diagnosis (Odds ratio (OR) 0.24 (95% CI: 0.03-1.73), p = 0.16

2017 Breast PubMed abstract

18. The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials (Full text)

The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials In everyday practice, angiotensin converting enzyme inhibitors and beta-blockers are cornerstone treatments in patients with (cardio-)vascular disease. Clear data that evaluate the effects of the combination of these agents on morbidity and mortality are lacking.In

2017 Cardiovascular Drugs and Therapy PubMed abstract

19. Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer’s disease (Full text)

Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer’s disease Cognitive improvement has been reported in patients receiving centrally acting angiotensin-converting enzyme inhibitors (C-ACEIs).To compare cognitive decline and survival after diagnosis of Alzheimer's disease between people receiving C-ACEIs, non-centrally acting angiotensin-converting enzyme inhibitors (NC-ACEIs), and neither.Routine Mini-Mental State Examination (MMSE) scores were (...) extracted in 5260 patients receiving acetylcholinesterase inhibitors and analysed against C-/NC-ACEI exposure at the time of Alzheimer's disease diagnosis.In the 9 months after Alzheimer's disease diagnosis, MMSE scores significantly increased by 0.72 and 0.19 points per year in patients on C-ACEIs and neither respectively, but deteriorated by 0.61 points per year in those on NC-ACEIs. There were no significant group differences in score trajectories from 9 to 36 months and no differences in survival.In

2017 BJPsych open PubMed abstract

20. Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice

Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Prescrire IN ENGLISH - Spotlight ''Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice'', 1 June 2017 {1} {1} {1} | | > > > Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Hypertension treatment in diabetes patients aims to reduce the risk of complications: cardiovascular events, end-stage renal failure, deterioration of eyesight. Patients with diabetes are exposed to arterial damage, including coronary artery disease and stroke, and damage to the blood capillaries

2017 Prescrire